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Background: To assess inpatient healthcare burden of gout in the USA after an Emergency Department (ED) visit
and the predictors of gout-related hospitalizations.
Method: We used the 2009, 2010 and 2012 US National ED Sample (NEDS) data to examine the time trends in
inpatient visits with gout as the primary diagnosis. We used the 2012 NEDS data to assess multivariable-adjusted
predictors of length of hospital stay, discharge to home (versus other) and total charges for gout-related inpatient
visits.
Results: Of the 205,152 ED visits for gout as the primary diagnosis in 2012, 7.7 % resulted in hospitalization. In 2009,
2010 and 2012, 63 %, 63 % and 64.5 % of hospitalized patients were discharged home; respective durations of
hospital stay were 4.15, 4.00 and 3.86 days. Older age 50 to <65 years (ref <50), renal failure, heart failure,
osteoarthritis and diabetes were associated with a longer hospital stay and self-pay/uninsured status, hospital
location in the Midwest or Western USA with a shorter hospital stay for gout. Similar factors were associated with
total charges for gout-related admissions. Older age (65 to <80 and ≥80, relative to <50 years), diabetes, self-pay/no
charge insurance status, metropolitan area residence, and a longer length of hospital stay were associated with lower
odds of discharge to home; and self-pay/no charge (uninsured) status was associated with higher odds of discharge to
home, compared to Medicare coverage.
Conclusions: Using a national sample, we noted declining duration of hospital stay and identified factors associated
with the length of hospital stay, discharge to home and charges for gout hospitalization following an ED visit.
Future studies should examine whether better management of comorbidities in patients with gout can further
reduce utilization and cost of gout-related hospitalizations.
Keywords: Gout, Inpatient utilization, Hospitalization, Comorbidity, Predictors, Length of stay, Hospital discharge,
Resource utilization, ChargesBackground
Gout is the most common form of inflammatory arthritis
in adults that affects up to 8.3 million Americans [1];
prevalence in European countries is similar at >1 % [2]. In
the presence of comorbidities that frequently accompany
gout, such as renal failure, heart failure (HF) and hyper-
tension, the treatment of gout can be challenging [3]. Poor
quality of gout care has been documented, related to these* Correspondence: jassingh@uab.edu
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prising that gout is associated with higher healthcare
utilization rates and cost [5].
Previous studies of gout-related utilization focused pri-
marily on costs [6, 7] or Emergency Department (ED)
visits [8, 9]. Hospitalization is expensive; 7 % Americans
hospitalized in 2012 accounted for 29 % of all health-
care expenses and cost $377 billion [10]. Studies of
hospitalization in gout are few (120 citations resulted
from a MEDLINE search on 16 December 2015 using
the keywords gout and hospitalization), which demon-
strates that this area is understudied. Studies have focused
on seasonal variation [11], quality of care or specific treat-
ment patterns [12–15], time trends [16], economic burdenle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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gout population [5, 17]. Several knowledge gaps exist. To
our knowledge, none of the previous studies examined
predictors of inpatient utilization or disposition after
hospitalization for gout. Most studies except one study [16]
used non-representative samples from tertiary care centers
[12–15] or combined all crystalline diseases [12, 15, 17],
which limited the generalizability of findings to general
populations with gout.
Thus, there are big knowledge gaps in our understand-
ing of the impact of gout on inpatient healthcare
utilization. Our study objective was to address the follow-
ing key questions using the data from the US National ED
Sample (NEDS): (1) which specific comorbidities and pa-
tient factors are associated with higher inpatient health-
care utilization, discharge disposition and charges in gout;
(2) what is the magnitude and direction of these associa-
tions; and (3) whether inpatient utilization due to gout is
increasing or decreasing over time.
Methods
Data source and study population
We performed this study using the discharge data from
the National Emergency Department Sample (NEDS),
Healthcare Cost and Utilization Project (HCUP), pro-
vided by the Agency for Healthcare Research and Quality
(AHRQ) [18]. NEDS is the largest, all-payer US ED data-
base that contains a 20 % stratified sample of ED visits
from across the USA [18]. The HCUP State Emergency
Department Databases (SEDD) and the State Inpatient
Databases (SID) provide data for NEDS [18]. The SEDD
and SID capture discharge information on ED visits that
do not result versus that result in an admission to the
same hospital, respectively. Thus, the denominators for
ED-related inpatient admissions (all ED visits) are avail-
able in this database. Thirty states, including 950 US
hospitals, contributed data in 2012. NEDS contains
event-level data. NEDS provides appropriate weights to
obtain weighted national estimates. In 2012, 31 million
ED visits were weighted to calculate the national esti-
mates related to 134 million ED visits in the USA [18].
NEDS is publicly available. For this study, we limited
analyses to hospitalization with gout as the primary
diagnosis in those who had gout-related ED visits. We
identified gout-related visits using the International
Classification of Diseases, Ninth revision, Common
Modification (ICD-9-CM) code of 274.xx in the re-
spective visit (a code listed as primary for the index ED
visit for ED-visit counts and for the index inpatient visit
for inpatient visit counts), an approach shown to be
valid previously [19]. The Institutional Review Board at
the University of Alabama at Birmingham approved the
study and waived the need for written informed con-
sent for this database study.Outcomes of interest and covariates
Study outcomes of interest in patients hospitalized with
gout as the primary diagnosis after an ED visit were: (1)
duration of hospital stay; (2) discharge to home; and (3)
total charges (ED and inpatient).
In addition to the reasons for ED visit (diagnoses and
procedures), NEDS includes other important patient/
hospital characteristics, such as age, sex, insurance status,
residence (urban versus rural), and the annual median
household income estimated using residential zip code.
Hospital characteristics include geographical region, lo-
cation in metropolitan or non-metropolitan area, and
whether the hospital is teaching versus non-teaching.
For each NEDS visit, up to 15 ICD-9-CM diagnostic
codes, nine ICD-9-CM procedures and 15 additional
procedures coded using Current Procedural Terminology
(CPT) are provided, which we used to assess comorbidities.
Statistical analysis
We used 2009, 2010 and 2012 data to examine time trends
in the length of hospital stay and the proportion of patients
discharged to home, since 2011 data had data duplication
issues and were not available from AHRQ at the time of
study conduct (https://www.hcup-us.ahrq.gov/db/nation/
neds/2011NEDSErrataNotification022415.pdf). We used
the 2012 NEDS data (most recent data available) to analyze
whether patient and hospital factors were associated with
outcomes following inpatient admission with gout as the
primary diagnosis after an ED visit (disposition to home;
length of hospital stay; total hospital charges (ED plus
inpatient)). We included prespecified patient and hospital
characteristics listed in covariate section (see paragraph
above) as potential predictors. We performed multivariable-
adjusted logistic regression (discharge disposition) or linear
regression (charges, length of stay) using SAS version 9.1
(SAS Institute, Inc., Cary, NC, USA). Analyses were
performed for log odds of charges and duration of hospital
stay due to their skewed distribution; the log transformation
of each variable showed normal distribution.
Results
Patient characteristics
Of the 205,152 ED visits for gout as the primary diagnosis in
2012, 7.7 % resulted in a hospital admission (Table 1). Char-
acteristics of patients with gout-related ED visit (overall), as
well by whether an ED visit resulted in a hospitalization or
not are provided (Table 1). Those who were admitted to the
hospital were more likely to be female, older, living in a
metropolitan area, or have higher household income, have
Medicare as primary payer, more likely to have comorbidities
and were seen at a hospital located in the Northeast or seen
at a Metropolitan, teaching hospital (Table 1).
Duration of hospital stay with gout as the primary
diagnosis seemed to diagnosis decreased significantly
Table 1 Demographic characteristics for 2012 NEDS study population
2012 NEDS (all) 2012 NEDS, not admitted 2012 NEDS who
were admitted
P value, not admitted
vs. admitted
N = 205,152 N = 189,255 N = 15,870
Age, in years
mean (SE) 55.44 (0.16) 54.50 (0.16) 66.66 (0.35) <0.0001
Sex
Female 46,839 (22.83) 41,818 (22.10) 5,021 (31.64) <0.0001
Patient location (residence) <0.0001
Micropolitan/not metro 47,371 (23.19) 45,563 (24.17) 1,808 (11.48)
Metropolitan (large or small) 156,905 (76.81) 142,958 (75.83) 13,948 (88.52)
Median household income <0.0001
1st quartile (<$38,999) 81,588 (40.71) 76,396 (41.23) 5,192 (33.47)
2nd quartile ($39,000 to $47,999) 48,791 (24.35) 45,224 (24.46) 3,567 (23.00)
3rd quartile ($48,000 to $62,999) 40,462 (20.19) 37,054 (20.04) 3,409 (21.98)
4th quartile ($63,000 or more) 29,554 (14.75) 26,211 (14.18) 3,343 (21.55)
Primary payer <0.0001
Medicare 72,568 (35.41) 62,733 (33.18) 9,835 (62.02)
Medicaid 27,556 (13.45) 25,773 (13.63) 1,783 (11.25)
Private insurance 51,329 (25.05) 48,730 (25.77) 2,599 (16.39)
Self-pay/no charge 45,241 (22.07) 44,068 (23.30) 1,173 (7.40)
Other 8,254 (4.03) 7,788 (4.12) 466 (2.94)
Hospital region <0.0001
Northeast 35,976 (17.54) 31,314 (16.54) 4,661 (29.37)
Midwest 40,729 (19.85) 37,434 (19.78) 3,295 (20.76)
South 97,904 (47.72) 92,088 (48.65) 5,817 (36.65)
West 30,543 (14.89) 28,446 (15.03) 2,097 (13.21)
Teaching status of hospital <0.0001
Metropolitan non-teaching or non-metro 125,106 (60.98) 118,362 (62.53) 6,744 (42.49)
Metropolitan teaching 80,047 (39.02) 70,902 (37.47) 9,126 (57.51)
Comorbidities
Coronary heart disease 13,548 (6.60) 9436 (4.99) 4,112 (25.91) <0.0001
Hyperlipidemia 23,862 (2.94) 17,829 (9.42) 6,033 (38.02) <0.0001
Renal failure 13,176 (6.42) 6,500 (3.43) 6,676 (42.07) <0.0001
Heart failure 10,029 (4.89) 6,455 (3.41) 3,574 (22.52) <0.0001
Hypertension 84,352 (41.12) 71,709 (37.88) 12,644 (79.67) <0.0001
Diabetes 32,774 (15.98) 26,653 (9.42) 6,121 (38.02) <0.0001
COPD 5,487 (2.67) 3,714 (1.96) 1,773 (11.17) <0.0001
Osteoarthritis 6,755 (3.29) 4,253 (2.25) 2,502 (15.77) <0.0001
NEDS National Emergency Department Sample, SE standard error, COPD chronic obstructive pulmonary disease
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which was significant (Table 2; p <0.01 to p <0.001 on a
paired t test for varying assumption of correlation coeffi-
cient ranging from 0.80 to −0.80, respectively). This corre-
sponded to a decrease of duration of hospital stay by
6.99% over 4 years or a reduction by 1.7 %/year roughly.The observations were similar for gout as primary or
secondary diagnosis. Respectively, 63 %, 63 % and 64.5 %
patients with a primary diagnosis of gout and 57.7 %, 57.7
% and 57.2 % for those with gout as primary or secondary
diagnosis were discharged home from the hospital, in
years 2009, 2011 and 2012, respectively (Table 2).
Table 2 Outcomes of patients with a hospital admission for gout after an Emergency Department (ED) visit
2009 NEDS 2010 NEDS 2012 NEDS
Duration of hospital stay, in days
Gout as primary diagnosis for ED visit, mean (SE) 4.15 (0.08) 4.00 (0.07) 3.86 (0.06)
Gout primary or secondary diagnosis for ED visit, mean (SE) 4.96 (0.05) 4.81 (0.04) 4.69 (0.05)
Hospitalization disposition for gout as as the primary diagnosis, n (%)
Discharged home 9,634 (63.02) 10,999 (63.22) 10,232 (64.47)
Skilled nursing facility, intermediate care facility, or another type of facility 2,934 (19.19) 3,188 (18.33) 2,835 (17.86)
Transferred to short-term hospital 104 (0.68) 148 (0.85) 92 (0.58)
Home health care 2,447 (16.00) 2,908 (16.71) 2,556 (16.10)
Against medical advice 118 (0.77) 115 (0.66) 134 (29.82)
Died 52 (0.34) 39 (0.23) 22 (0.14)
Hospitalization disposition with gout as the primary or secondary diagnosis*, n (%)
Discharged home 257,348 (57.72) 272,281 (57.75) 285,080 (57.22)
Skilled nursing facility, intermediate care facility, and another type of facility 94,314 (21.15) 98,853 (20.97) 104,135 (20.90)
Transferred to short-term hospital 12,241 (2.75) 12,241 (2.60) 13,206 (2.65)
Home healthcare 68,116 (15.28) 75,237 (15.96) 81,885 (16.44)
Against medical advice 3,524 (0.79) 3,516 (0.75) 4,198 (0.84)
Died 10,069 (2.26) 9,133 (1.94) 9,547 (1.92)
NEDS National Emergency Department Sample, ED emergency department, SE standard error
*Statistics for hospitalizations for which gout was either primary or secondary diagnosis
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disposition and total charges in patients hospitalized with
gout as primary diagnosis
In multivariable-adjusted linear regression analyses, age
50 to <65 years (compared to <50 years) and the presence
of renal failure, heart failure, diabetes or osteoarthritis were
associated with a longer hospital stay for a hospitalization
due to gout (Table 3). In contrast, self-pay/no charge (un-
insured) or private insurance status, and hospital location
in Midwest or Western USA, were associated with a
shorter hospital stay for a gout hospitalization (Table 3).
In multivariable-adjusted analyses, older age (65 to <80
and ≥80, relative to <50 years), patient residence in metro-
politan area, concomitant diabetes, and a longer length of
hospital stay were associated with significantly lower
odds of discharge to home (Table 4); self-pay/no charge
(uninsured) status was associated with higher odds of
discharge to home, compared to Medicare coverage.
In multivariable-adjusted analyses, older age 50 to <65
(relative to <50 years), metropolitan area residence,
Western USA hospital location and the presence of
renal failure or heart failure were associated with higher
total charges in hospitalized patients, while those with
“other” primary payer (compared to Medicare coverage)
had lower total hospital charges (Table 5).
Discussion
Our study of hospitalization with gout as the primary diag-
nosis after an ED visit using a national US sample providesan understanding of the predictors of healthcare and eco-
nomic burden of gout in the USA and the time trends in
hospitalizations due to gout. Several findings are novel and
merit further discussion.
Time trends were noted in the length of gout-related
hospitalization. The length of hospital stay decreased by 1.7
%/year. This decline was similar to that noted for acute myo-
cardial infarction at 1.8 %/year from 2001 to 2011 [20] and
knee/hip arthroplasty at 1.5 %/year from 2003 to 2010 [21],
but larger than the 0.2 % annual reduction in length of stay
for all hospitalizations in the USA from 2003 to 2012 [22].
Availability of two new urate-lowering therapies since 2009
(febuxostat and pegloticase) may have contributed to this
greater reduction. We are unaware of any national quality
improvement campaigns for hospitalized gout patients over
this time period, or favorable national trends in quality of
gout care in outpatient setting that could lead to this de-
crease. The database did not have any data on inpatient gout
quality indicators or medication use, and therefore we were
unable to assess this directly using the database. We caution
that, even though we found that the difference between 2009
and 2012 hospitalization length of stay was significant and
we calculated it based on a wide range of correlation coeffi-
cients (+0.80 to −0.80), a more appropriate test for the time
trend is repeated measurement mixed model analysis,
which could not be performed due to the non-availability
of patient-level data.
We identified several patient and hospital characteris-
tics that were significantly associated with the duration
Table 3 Predictors of log of duration of hospital stay among patients with gout who were admitted to the hospital after presenting
to the Emergency Department (ED) with gout using linear regression
Univariate Multivariable-adjusted
B-estimate (95 % CI) P value B-estimate (95 % CI) P value
Age
<50 Ref Ref
50 to <65 0.12 (0.07, 0.17) <0.0001 0.07 (0.02, 0.12) 0.0081
65 to <80 0.20 (0.14, 0.25) <0.0001 0.07 (0.01, 0.14) 0.0287
≥80 0.22 (0.16, 0.27) <0.0001 0.09 (0.01, 0.17) 0.0234
Gender
Female Ref Ref
Male −0.08 (−0.12, −0.04) <0.0001 −0.04 (−0.08, 0.00) 0.0518
Median household income
1st quartile Ref Ref
2nd quartile −0.01 (−0.06, 0.03) 0.5966 −0.01 (−0.05, 0.04) 0.7384
3rd quartile −0.03 (−0.09, 0.02) 0.2095 −0.03 (−0.08, 0.03) 0.3354
4th quartile −0.01 (−0.06, 0.04) 0.6627 −0.02 (−0.07, 0.03) 0.4458
Primary payer
Medicare Ref Ref
Medicaid −0.09 (−0.16, −0.02) 0.0093 −0.05 (−0.12, 0.03) 0.2501
Private insurance −0.14 (−0.19, −0.09) <0.0001 −0.07 (−0.13, −0.01) 0.02
Self-pay/no charge −0.25 (−0.31, −0.19) <0.0001 −0.16 (−0.23, −0.09) <0.0001
Other −0.17 (−0.26, −0.08) 0.0003 −0.08 (−0.18, 0.02) 0.1264
Patient location (residence)
Micropolitan/not metro Ref Ref
Metro (large or small) 0.02 (−0.05, 0.08) 0.6063 0.02 (−0.05, 0.09) 0.4927
Hospital region
Northeast Ref Ref
Midwest −0.13 (−0.18, −0.07) <0.0001 −0.12 (−0.18, −0.07) <0.0001
South −0.03 (−0.09, 0.02) 0.2100 −0.02 (−0.08, 0.03) 0.4363
West −0.14 (−0.21, −0.08) <0.0001 −0.11 (−0.18, −0.04) 0.0025
Teaching status of hospital
Metropolitan non-teaching or non-metro Ref Ref
Metropolitan teaching 0.03 (−0.01, 0.07) 0.1344 0.01 (−0.03, 0.06) 0.5442
Comorbidities
CHD (ref: no) 0.06 (0.02, 0.10) 0.0018 0.01 (−0.04, 0.05) 0.8225
Hyperlipidemia (ref: no) −0.00 (−0.04, 0.03) 0.9381 −0.04 (−0.08, 0.01) 0.258
Renal failure (ref: no) 0.13 (0.09, 0.17) <0.0001 0.10 (0.06, 0.14) <0.0001
Heart failure (ref: no) 0.14 (0.10, 0.17) <0.0001 0.08 (0.04, 0.12) 0.0002
Hypertension (ref: no) 0.04 (−0.00, 0.08) 0.0832 −0.04 (−0.08, 0.01) 0.0938
Diabetes (ref: no) 0.09 (0.05, 0.13) <0.0001 0.05 (0.01, 0.09) 0.0078
COPD (ref: no) 0.04 (−0.02, 0.09) 0.2023 −0.02 (−0.08, 0.04) 0.4902
Osteoarthritis (ref: no) 0.08 (0.03, 0.12) 0.0027 0.06 (0.01, 0.11) 0.0250
Significant beta coefficients are in bold
CI confidence interval, Ref reference category, CHD coronary heart disease, COPD chronic obstructive pulmonary disease
For interpretation in numeric terms for hospital stay, the coefficients from this regression with log (hospital stay) as an outcome should be transformed as ex, where x= beta-
estimate. For example, compared to age <50, hospital stay for ages 50 to <65 was 1.07 times higher (beta coefficient = 0.07; e0.07 = 1.07). On the other hand, compared to
Medicare, private insurance was associated with 0.93 times (beta coefficient = −0.07; e−0.07 = 0.93) and self-pay/no charge with 0.85 times (beta coefficient = −0.16; e−0.16 = 0.85),
the duration of hospital stay. Positive beta-coefficients in this regression with log outcome indicate a longer length of stay and negative beta-coefficients indicate a shorter length
of stay. Patients residing in the Midwest had 0.89 times and in the West had 1.57 times the duration of hospital stay (reference, Northeast). Compared to patients without each
condition, patients with renal failure had 1.10 times, heart failure, 1.08 times, diabetes, 1.05 times and osteoarthritis, 1.06 times, the duration of hospital stay
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Table 4 Predictors of discharge to home (reference, non-home discharge) among patients who had a hospital admission after
presenting to the Emergency Department (ED) with gout using logistic regression
Univariate Multivariable-adjusted
Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Age
<50 Ref
50 to <65 0.53 (0.38, 0.73) 0.0001 0.69 (0.47, 1.01) 0.0573
65 to <80 0.15 (0.11, 0.20) <0.0001 0.25 (0.16, 0.37) <0.0001
≥80 0.08 (0.06, 0.11) <0.0001 0.13 (0.09, 0.20) <0.0001
Gender
Female Ref Ref
Male 1.81 (1.55, 2.12) <0.0001 1.16 (0.97, 1.39) 0.1128
Median household income
1st quartile (<$38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 1.05 (0.85, 1.31) 0.6413 1.12 (0.87, 1.44) 0.3930
3rd quartile ($48,000 to $62,999) 0.89 (0.70, 1.12) 0.2998 1.02 (0.77, 1.36) 0.8844
4th quartile ($63,000 or more) 0.81 (0.64, 1.01) 0.0618 1.09 (0.84, 1.42) 0.5083
Primary payer
Medicare Ref Ref
Medicaid 3.82 (2.92, 5.00) <0.0001 1.49 (1.00, 2.24) 0.0527
Private insurance 3.28 (2.62, 4.11) <0.0001 1.29 (1.00, 1.67) 0.0523
Self-pay/no charge 11.42 (7.30, 17.85) <0.0001 2.77 (1.54, 4.96) 0.0006
Other 4.59 (2.50, 8.42) <0.0001 1.49 (0.79, 2.81) 0.2218
Patient location (residence)
Micropolitan/not metro Ref Ref
Metropolitan (large or small) 0.84 (0.67, 1.07) 0.1589 0.72 (0.54, 0.97) 0.0282
Hospital region
Northeast Ref Ref
Midwest 1.17 (0.89, 1.54) 0.2682 0.98 (0.73, 1.31) 0.8700
South 1.28 (1.00, 1.62) 0.0477 1.20 (0.90, 1.59) 0.2138
West 1.58 (1.17, 2.13) 0.0028 1.24 (0.91, 1.69) 0.1821
Teaching status of hospital
Metropolitan non-teaching or non-metro Ref Ref
Metropolitan teaching 1.04 (0.86, 1.24) 0.7066 1.09 (0.89, 1.34) 0.3909
Comorbidities
Coronary heart disease (ref: no) 0.58 (0.48, 0.69) <0.0001 0.94 (0.75, 1.16) 0.5433
Hyperlipidemia (ref: no) 0.89 (0.78, 1.03) 0.1152 1.18 (0.99, 1.39) 0.0604
Renal failure (ref: no) 0.61 (0.52, 0.73) <0.0001 0.87 (0.71, 1.06) 0.1528
Heart failure (ref: no) 0.52 (0.44, 0.61) <0.0001 0.88 (0.72, 1.07) 0.2002
Hypertension (ref: no) 0.77 (0.64, 0.93) 0.0050 1.09 (0.86, 1.39) 0.4554
Diabetes (ref: no) 0.68 (0.58, 0.78) <0.0001 0.78 (0.64, 0.95) 0.0121
COPD (ref: no) 0.58 (0.46, 0.72) <0.0001 0.79 (0.60, 1.04) 0.0871
Osteoarthritis (ref: no) 0.60 (0.49, 0.74) <0.0001 0.85 (0.68, 1.06) 0.1414
Length of stay, in days (per day increase) 0.79 (0.76, 0.83) <0.0001 0.80 (0.76, 0.83) <0.0001
Significant odds ratios are in bold
CI confidence interval, Ref reference category, COPD chronic obstructive pulmonary disease
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Table 5 Predictors of log of inpatient hospital charges among patients with gout who were admitted to the hospital after
presenting to the Emergency Department (ED) with gout using linear regression
Univariate Multivariable-adjusted
B-estimate (95 % CI) P value B-estimate (95 % CI) P value
Age
<50 Ref Ref
50– <65 0.11 (0.03, 0.19) 0.0055 0.10 (0.02, 0.18) 0.0129
65– <80 0.13 (0.06, 0.21) 0.0009 0.06 (−0.03, 0.16) 0.1681
≥80 0.13 (0.05, 0.21) 0.0024 0.04 (−0.07, 0.14) 0.4682
Gender
Female Ref Ref
Male −0.02 (−0.07, 0.03) 0.4747 −0.02 (−0.07, 0.03) 0.4667
Median household income
1st quartile (<$38,999) Ref Ref
2nd quartile (39,000 to 47,999) 0.02 (−0.09, 0.12) 0.7360 −0.02 (−0.12, 0.08) 0.7445
3rd quartile (48,000 to 62,999) 0.09 (−0.03, 0.20) 0.1558 0.01 (−0.11, 0.13) 0.8524
4th quartile ($63,000 or more) 0.10 (−0.05, 0.26) 0.1891 0.00 (−0.17, 0.16) 0.9868
Primary payer
Medicare Ref Ref
Medicaid −0.04 (−0.15, 0.06) 0.4274 −0.05 (−0.16, 0.06) 0.3690
Private insurance −0.11 (−0.18, −0.03) 0.0090 −0.07 (−0.16, 0.02) 0.1432
Self-pay/no charge −0.11 (−0.21, 0.00) 0.0851 −0.05 (−0.17, 0.07) 0.4134
Other −0.15 (−0.3, 0.02) 0.0814 −0.25 (−0.42, −0.08) 0.0040
Patient location (residence)
Micropolitan/not metro Ref Ref
Metro (large or small) 0.23 (0.12, 0.35) 0.0001 0.22 (0.11, 0.33) 0.0001
Hospital region
Northeast Ref Ref
Midwest −0.13 (−0.32, 0.06) 0.1889 −0.13 (−0.33, 0.07) 0.2064
South −0.13 (−0.33, 0.08) 0.2283 −0.11 (−0.33, 0.11) 0.3367
West 0.40 (0.18, 0.61) 0.0003 0.45 (0.24, 0.66) <0.0001
Teaching status of hospital
Metropolitan non-teaching or non-metro Ref Ref
Metropolitan teaching 0.01 (−0.12, 0.15) 0.8413 0.00 (−0.13, 0.13) 0.9667
Comorbidities
CHD (ref: no) 0.10 (0.03, 0.16) 0.0053 0.04 (−0.03, 0.11) 0.2616
Hyperlipidemia (ref: no) −0.02 (−0.07, 0.03) 0.4388 −0.05 (−0.10, 0.00) 0.0618
Renal failure (ref: no) 0.15 (0.09, 0.22) <0.0001 0.12 (0.07, 0.18) <0.0001
Heart failure (ref: no) 0.16 (0.10, 0.23) <0.0001 0.13 (0.06, 0.19) 0.0001
Hypertension (ref: no) −0.00 (−0.07, 0.07) 0.9331 −0.05 (−0.12, 0.03) 0.2028
Diabetes (ref: no) 0.08 (0.02, 0.13) 0.0058 0.04 (−0.02, 0.10) 0.1590
COPD (ref: no) 0.10 (0.02, 0.18) 0.0167 0.06 (−0.02, 0.14) 0.1744
OA (ref: no) 0.01 (−0.07, 0.09) 0.7755 0.02 (−0.05, 0.10) 0.5026
Significant odds ratios are in bold
CI confidence interval, Ref reference category, CHD coronary heart disease, COPD chronic obstructive pulmonary disease, OA osteoarthritis
For interpretation in numeric terms for hospital charges, the coefficients from this regression with log (hospital charges) as an outcome should be transformed as
ex, where x = beta-estimate. For example, compared to age <50, hospital charges for ages 50 to <65 was 1.10 times higher (beta coefficient = 0.10; e0.10 = 1.10). On
the other hand, compared to Medicare, “other” insurance was associated with 0.78 times the duration of hospital stay (beta coefficient =− 0.25; e−0.25 = 0.78).
Positive beta coefficients in this regression with log outcome indicate higher charges and negative beta coefficients indicate lower hospital charges. Patients
residing in metropolitan area had hospital charges 1.25 times (reference, non-metro) and in the West 1.57 times hospital charges (reference, Northeast); patients
with renal failure had 1.12 times charges and with heart failure, 1.24 times hospital charges
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charges. The study of factors associated with discharge
to home for gout-related hospitalization adds to the
current knowledge. We found that self-pay/uninsured
status was associated with a higher likelihood and older
age, metropolitan area residence, diabetes and a longer
length of hospital stay were associated with a lower like-
lihood of discharge to home. In the absence of previous
studies of predictors of discharge disposition of patients
hospitalized for gout, these findings offer a new insight.
Financial burden for self-pay patients and better social
support for patients in non-metropolitan areas [23] may
be the respective reasons for the higher likelihood of dis-
charge to home in these patients. Recognition that these
characteristics associated with discharge disposition can
now allow identification of high-risk patients, when they
are admitted to the hospital with gout. Older age is asso-
ciated with nursing home placement due to higher burden
of medical illnesses [24], therefore it is not surprising to
see it inversely related to discharge to home. Involvement
of social services and early discharge planning, especially
in those at the highest risk, might further increase the pro-
portion of hospitalized gout patients discharged to home.
Diabetes was associated with nursing home admission
in patients hospitalized for heart failure [25]. Our study
finding that diabetes is associated with lower odds of
discharge to home extends this finding to patients with
gout. Diabetes is associated with a decline in mobility
and functional status [26]. Limitation of mobility is a
risk factor for discharge to non-home settings after
hospitalization [24]. This might explain the impact of
diabetes on post-hospitalization discharge disposition.
Future studies should also examine as to whether specific
aspects of diabetes (complications such as neuropathy/
nephropathy/retinopathy versus amyotropy versus current
blood glucose levels) are responsible for this association.
We also found that several (but not all) comorbidities,
namely heart failure, renal failure, diabetes and osteoarthritis,
were associated with a longer hospital stay in patients admit-
ted for gout for after an ED visit. For an easier interpretation
of regression coefficients for the duration of hospital stay
and hospital charges, we added table legends that provides
the reader with transformation of the beta coefficients
(i.e., exponentiation); a negative coefficient in these tables
assessing log of the outcome variable translates to <1 mul-
tiple, and a positive coefficient to >1 multiple, compared
to the reference category. We hypothesize that treatments
frequently used in patients admitted with acute gout, may
contribute to worsening of renal function or heart failure,
which in turn can prolong the hospital stay. These include
corticosteroid use associated with sodium and fluid reten-
tion [27–29] that can worsen hypertension and potentially
heart failure; non-steroidal anti-inflammatory drugs
(NSAIDs) that can lead to new onset/worsening renalfunction in patients with pre-existing chronic renal failure,
diabetic nephropathy and/or heart failure [30–32]; and
NSAID-associated fluid retention that can worsen heart
failure and renal failure [27]. Use of lower doses of
NSAIDs or corticosteroids to avoid worsening of renal or
heart failure with full doses (due to relative contraindica-
tions), as suggested (but not endorsed) in the 2012 Ameri-
can College of Rheumatology (ACR) gout guideline [33],
may also lead to a longer time to resolve a gout flare in
these patients, and hence a longer hospital stay. These co-
morbidities are associated with a higher risk of gout flares
[34], and it is possible that gout flares are more severe in
patients with these concomitant comorbidities, which re-
quires a longer hospital stay for optimal treatment and
resolution.
Whether osteoarthritis-associated symptoms worsen dur-
ing acute gout flares is not well described. This is possible,
and may be contributing to a longer hospitalization in these
patients. Chronic disability and functional limitation associ-
ated with osteoarthritis may also contribute to a longer
hospitalization in these patients with gout. Whether a
shorter hospital stay associated with certain hospital and in-
surance characteristics, such as self-pay/uninsured status,
Midwest or West US location, is due to practice pattern var-
iations or other reasons, needs to be examined in future
studies. Factors associated with higher total charges were
similar to that noted for length of hospital stay, which adds
to the consistency of findings. It remains to be seen, whether
triage pathways or targeted interventions that optimize these
comorbidities in high-risk gout patients can improve the
outcomes and reduce healthcare utilization and cost.
Our study has several limitations. We examined ED-
associated inpatient utilization due to gout, the main ob-
jective of our study. Some hospitalizations may occur
from non-ED settings and our study findings are likely
not generalizable to those, since they are likely to differ
in outcomes. NEDS counts visits, not patients, therefore
it is not possible at present to assess the occurrence of
repeat visits by the same patients to the ED and factors
associated with this phenomenon; these sort of analyses
could provide great insights into gout-related ED utilization.
NEDS does not provide laboratory or pharmacy costs, which
would allow a more complete assessment of resource
utilization. NEDS provides data on charges, not actual cost
to the hospital or the actual expense paid by the insurer.
The charges and the costs/expenses can differ slightly or by
a significant margin, depending on how much the charges
are inflated relative to the cost of services. The non-availabil-
ity of the 2011 data due to data duplication issues limited
our ability to do detailed time trend analyses, a secondary
study objective. The availability of these would have in-
formed time-trend analyses. There was no impact of these
missing 2011 data on the main analyses related to predictors
of discharge to home, charges and the length of hospital
Singh and Yu Arthritis Research & Therapy  (2016) 18:57 Page 9 of 10stay, since analyses were performed on the data from the
most recent year, i.e., 2012.
Our study has several strengths. The NEDS allowed us
to produce national estimates about ED-related inpatient
visits due to gout in the USA, given the weighting
scheme provided. Its large sample size and representa-
tiveness allows study of uncommon/rare outcomes and
generalizability of study findings. Several common co-
morbidities seen in gout, such as heart disease, renal
failure and osteoarthritis were adjusted, which make these
estimates relevant for gout patients. Findings were robust
with a great similarity of factors associated with length of
hospital stay and charges.
Conclusions
In conclusion, our study provides US estimates of health-
care utilization and burden related to hospitalization with
gout as the primary diagnosis after an ED visit. We found
that several comorbidities and patient and hospital charac-
teristics were associated with a lower risk of discharge to
home, a longer hospital stay and higher total charges in
patients with gout. Findings from our study should lead to
further research into modifiable predictors of outcomes of
gout-associated hospitalization. This advance in know-
ledge can spur the development of potential interventions
to reduce inpatient healthcare utilization and costs due to
gout in settings and optimize outcomes.
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